These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes. De Smet R; Dhondt A; Eloot S; Galli F; Waterloos MA; Vanholder R Nephrol Dial Transplant; 2007 Jul; 22(7):2006-12. PubMed ID: 17468506 [TBL] [Abstract][Full Text] [Related]
28. The search for the uremic toxin: the case for carbamoylation of amino acids and proteins. Kraus LM; Kraus AP Wien Klin Wochenschr; 1998 Aug; 110(15):521-30. PubMed ID: 9782570 [TBL] [Abstract][Full Text] [Related]
29. New approaches to the removal of protein-bound toxins from blood plasma of uremic patients. Sarnatskaya VV; Yushko LA; Sakhno LA; Nikolaev VG; Nikolaev AV; Grinenko DV; Mikhalovsky SV Artif Cells Blood Substit Immobil Biotechnol; 2007; 35(3):287-308. PubMed ID: 17573628 [TBL] [Abstract][Full Text] [Related]
30. Studies on uremic toxins; structure-activity correlation in H-Asp(Gly)-OH. Abiko T; Kumikawa M; Dazai S; Takahashi H; Ishizaki M; Sekino H Biochem Biophys Res Commun; 1978 May; 82(2):707-15. PubMed ID: 666867 [No Abstract] [Full Text] [Related]
31. The uraemic retention solute para-hydroxy-hippuric acid attenuates apoptosis of polymorphonuclear leukocytes from healthy subjects but not from haemodialysis patients. Cohen G; Raupachova J; Wimmer T; Deicher R; Hörl WH Nephrol Dial Transplant; 2008 Aug; 23(8):2512-9. PubMed ID: 18319358 [TBL] [Abstract][Full Text] [Related]
32. [Changes in protein fractions and lipoproteins in azothemia]. Derevianko NA Lab Delo; 1969; 1():37-8. PubMed ID: 4185356 [No Abstract] [Full Text] [Related]
33. [Clinical and metabolic consequences of uremic toxicity]. Rutkowski P Przegl Lek; 2006; 63(4):209-17. PubMed ID: 17080744 [TBL] [Abstract][Full Text] [Related]
34. The immune system in uremia and during its treatment. Haag-Weber M; Hörl WH New Horiz; 1995 Nov; 3(4):669-79. PubMed ID: 8574597 [TBL] [Abstract][Full Text] [Related]
35. Beyond phosphate--role of uraemic toxins in cardiovascular calcification. Nikolov I; Joki N; Drüeke T; Massy Z Nephrol Dial Transplant; 2006 Dec; 21(12):3354-7. PubMed ID: 17005531 [No Abstract] [Full Text] [Related]
36. Protein damage and inflammation in uraemia and dialysis patients. Galli F Nephrol Dial Transplant; 2007 Jul; 22 Suppl 5():v20-36. PubMed ID: 17586842 [TBL] [Abstract][Full Text] [Related]
37. Separation, isolation, and identification of middle molecules. Bergström J; Fürst P; Zimmerman L Artif Organs; 1981; 4 Suppl():5-7. PubMed ID: 7295096 [No Abstract] [Full Text] [Related]
38. [Depurative efficiency of intermediate and large molecules with different hemodialysis modalities]. Maduell F Nefrologia; 2005; 25 Suppl 2():15-8. PubMed ID: 16050396 [TBL] [Abstract][Full Text] [Related]
39. Influence of uremic middle molecules on in vitro stimulated lymphocytes and interleukin-2 production. Severini G; Diana L; Di Giovannandrea R; Sagliaschi G ASAIO J; 1996; 42(1):64-7. PubMed ID: 8808461 [TBL] [Abstract][Full Text] [Related]
40. [Changes in the picture of chronic diseases on long-term hemodialysis treatment]. von Appen K; Ivanovich P; Klinkmann H; Stetsiuk E Urol Nefrol (Mosk); 1995; (5):25-7. PubMed ID: 8571479 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]